Acorda Therapeutics (ACOR) Tops Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sifel Sees Acorda's (ACOR) R&D Investments Panning Out in FY16/FY17; Affirms at 'Buy'
February 11, 2016 11:47 AM ESTSifel reaffirms Acorda Therapeutics (Nasdaq: ACOR) at Buy with a price target of $53 following the company's Q4 report earlier Thursday.
Analyst Thomas Shrader commented: Acorda released 4Q numbers again - including Ampyra sales of $122 million for 4Q and $437 million for 2015. The company... More
